Bone-marrow transplantation is an effective cell therapy but requires myeloablation, which increases infection risk and mortality. Recent lineage-tracing studies documenting that resident macrophage populations self-maintain independently of haematological progenitors prompted us to consider organ-targeted, cell-specific therapy. Here, using granulocytemacrophage colony-stimulating factor (GM-CSF) receptor-b-deficient (Csf2rb 2/2 ) mice that develop a myeloid cell disorder identical to hereditary pulmonary alveolar proteinosis (hPAP) in children with CSF2RA or CSF2RB mutations, we show that pulmonary macrophage transplantation (PMT) of either wild-type or Csf2rb-gene-corrected macrophages without myeloablation was safe and well-tolerated and that one administration corrected the lung disease, secondary systemic manifestations and normalized disease-related biomarkers, and prevented disease-specific mortality. PMTderived alveolar macrophages persisted for at least one year as did therapeutic effects. Our findings identify mechanisms regulating alveolar macrophage population size in health and disease, indicate that GM-CSF is required for phenotypic determination of alveolar macrophages, and support translation of PMTas the first specific therapy for children with hPAP.
Bone-marrow transplantation is an effective cell therapy but requires myeloablation, which increases infection risk and mortality. Recent lineage-tracing studies documenting that resident macrophage populations self-maintain independently of haematological progenitors prompted us to consider organ-targeted, cell-specific therapy. Here, using granulocytemacrophage colony-stimulating factor (GM-CSF) receptor-b-deficient (Csf2rb 2/2 ) mice that develop a myeloid cell disorder identical to hereditary pulmonary alveolar proteinosis (hPAP) in children with CSF2RA or CSF2RB mutations, we show that pulmonary macrophage transplantation (PMT) of either wild-type or Csf2rb-gene-corrected macrophages without myeloablation was safe and well-tolerated and that one administration corrected the lung disease, secondary systemic manifestations and normalized disease-related biomarkers, and prevented disease-specific mortality. PMTderived alveolar macrophages persisted for at least one year as did therapeutic effects. Our findings identify mechanisms regulating alveolar macrophage population size in health and disease, indicate that GM-CSF is required for phenotypic determination of alveolar macrophages, and support translation of PMTas the first specific therapy for children with hPAP.
Mutations in CSF2RA or CSF2RB, encoding GM-CSF receptor a or b, respectively, cause hPAP by impairing GM-CSF-dependent surfactant clearance by alveolar macrophages, resulting in progressive surfactant accumulation in alveoli and hypoxaemic respiratory failure [1] [2] [3] [4] [5] . Surfactant normally comprises a thin phospholipid/protein layer reducing tension on the alveolar surface 6 that is maintained by balanced secretion by alveolar type II epithelial cells and clearance by these cells and alveolar macrophages 7, 8 . PAP also occurs in people with GM-CSF autoantibodies (,85-90% of all patients with PAP) 9, 10 and mice with disruption of the GM-CSF gene Csf2 (refs 11, 12) or the GM-CSF receptor b-subunit gene Csf2rb (refs 13, 14) (Csf2 2/2 or Csf2rb 2/2 mice, respectively). Characteristics of PAP caused by disruption of GM-CSF signalling include typical lung histopathology (well preserved alveoli filled with surfactant and 'foamy' macrophages staining positive with periodic acid-Schiff (PAS) or oil red O); turbid, 'milky' appearing bronchoalveolar lavage (BAL) caused by accumulated surfactant and cell debris; and a diseasespecific pattern of biomarkers (increased GM-CSF (hPAP), M-CSF/CSF1 and MCP-1 in BAL fluid, and reduced mRNA for PU.1, PPARG and ABCG1 in alveolar macrophages) [1] [2] [3] [4] [5] [15] [16] [17] [18] [19] [20] .
Currently, no pharmacological therapy of hPAP exists and surfactant must be removed by whole-lung lavage, an inefficient, invasive procedure to physically remove excess surfactant [2] [3] [4] . In Csf2rb 2/2 mice, PAP was corrected by bone marrow transplantation (BMT) of wild-type (WT) 21 or Csf2rb-gene-corrected Csf2rb 2/2 haematopoietic stem/progenitor cells (HSPCs) 22 . However, in humans this approach resulted in death from infection before engraftment 2 , probably as a result of required myeloablation/immunosuppressive therapy. Since pulmonary GM-CSF is increased in hPAP [1] [2] [3] [4] [5] we hypothesized that macrophages administered directly into the lungs (pulmonary macrophage transplantation or PMT) without myeloablation would engraft and reverse the manifestations of hPAP.
We first validated Csf2rb 2/2 mice as a model of human hPAP by demonstrating that they had the same clinical, physiological, histopathological and biochemical abnormalities, disease biomarkers and natural history ( Fig. 1 and Extended Data Fig. 1 ) as children with hPAP 3 .
Characterization of macrophages before PMT
Bone-marrow-derived macrophages (BMDMs) from WT mice had morphology and phenotypic markers (F4/80 1 , CD11b Hi , CD11c 1 , CD14 1 , CD16/32 1 , CD64 1 , CD68 1 , CD115 1 , CD131 1 , SiglecF Low , MerTK 1 , MHC class II 1 , Ly6G 2 , CD3 2 , CD19 2 ) of macrophages (Extended Data Fig. 2a -c) and contained ,0.0125% lineage negative (Lin 2 ) Sca1 1 c-Kit 1 (LSK) cells. Clonogenic analysis indicated ,0.005% colony-forming units-granulocyte, monocyte/macrophage (CFU-GM) and no burstforming units-erythrocyte (BFU-E) or colony-forming units-granulocyte, erythrocyte, monocyte/macrophage, megakaryocyte (CFU-GEMM) progenitors (Extended Data Fig. 2d , e). Functional evaluation 23 showed that the BMDMs could clear surfactant (Extended Data Fig. 2f, g) . These results demonstrated that the cells used for PMT were highly purified, mature macrophages capable of surfactant clearance.
Efficacy of PMT of WT macrophages
To determine the therapeutic potential of PMT, Csf2rb 2/2 mice received WT (Csf2rb 1/1 ) BMDMs by PMT once (Fig. 1a) . One year later, PMTderived CD131 1 BAL cells were present ( Fig. 1b ), alveolar macrophages expressed Csf2rb (Extended Data Fig. 3a ), and BAL was markedly improved with respect to opacification ( Fig. 1c ), sediment ( Fig. 1c ) and microscopic cytopathology (Extended Data Fig. 3b ). Importantly, PMT nearly completely resolved the abnormal pulmonary histopathology ( Fig. 1d and Extended Data Fig. 3c ). Measurement of BAL turbidity and surfactant protein-D (SP-D) content ( Fig. 1e ), which reflect the extent of surfactant accumulation across the entire lung surface, confirmed the improvement in hPAP. BAL fluid biomarkers of hPAP were also improved ( Fig. 1f ). The effects of PMT were evident early, as demonstrated by detection of CD131 1 alveolar macrophages with Csf2rb mRNA and protein (not shown), reduced BAL opacification and cytopathology (not shown), BAL turbidity ( Fig. 1e ), SP-D ( Fig. 1e ) and BAL fluid biomarkers ( Fig. 1f ) 2 months after PMT, and reduced lung histopathology 4 months after PMT (not shown). In contrast, PMT of Csf2rb 2/2 BMDMs had no effect on BAL turbidity, SP-D content, or BAL fluid biomarkers (not shown), demonstrating that GM-CSF receptors on transplanted macrophages are important for the therapeutic effects.
To evaluate the effects of PMT on the alveolar macrophage population, we measured cellular biomarkers after PMT. Results showed that alveolar macrophages from PMT-treated Csf2rb 2/2 mice had increased mRNA for PU.1, Pparg and Abcg1, improvement was significant by 2 months, and the effects persisted 1 year after PMT ( Fig. 1g ).
Since Csf2rb 2/2 mice develop polycythaemia, a secondary consequence of hypoxaemia in chronic lung diseases 24 , we evaluated the effects of PMT on this systemic clinical manifestation. Notably, PMT corrected polycythaemia in Csf2rb 2/2 mice ( Fig. 1h ).
Finally, we evaluated the effects of PMT on hPAP-associated mortality by comparing the survival of PMT-treated and untreated Csf2rb 2/2 mice. PMT increased the lifespan of Csf2rb 2/2 mice by 107 days, from 555 (median; interquartile range 507-592) days to 662 (604-692) days ( Fig. 1i ). In separate studies of treated Csf2rb 2/2 mice surviving to 617 (604-631) days (561 (548-575) days after PMT of WT BMDMs), CD131 1 alveolar macrophages were still present and BAL turbidity remained low compared to untreated Csf2rb 2/2 mice that survived to 631 (631-631) days (optical density at 600 nm (OD 600 ) 5 0.75 6 0.17 versus 2.63 6 0.44; n 5 8, 4, respectively; P , 0.001). However, such long-term evaluation of laboratory abnormalities is obfuscated by reduced survival of untreated Csf2rb 2/2 mice.
These results demonstrate that PMT had a highly efficacious and durable therapeutic effect on the primary pulmonary and secondary systemic manifestations of hPAP in Csf2rb 2/2 mice.
Macrophage engraftment efficiency
We next evaluated the effects of cell dose (0.5, 1, 2 and 4 million) and repeated administration (one versus four monthly transplantations) on PMT efficacy (Extended Data Tables 2 and 3, respectively). Neither treatment significantly affected efficacy in the range evaluated, and one dose of 2 million cells was used for PMT in the remaining studies.
To determine whether WT macrophages had a survival advantage over Csf2rb 2/2 macrophages, we measured GM-CSF bioactivity in BAL fluid and found that it was detectable in Csf2rb 2/2 but not WT mice (Extended Data Fig. 1h ). WT macrophages had increased survival/proliferation compared to Csf2rb 2/2 macrophages in vitro ( Fig. 2a ) and accumulated to greater numbers after PMT in Csf2rb 2/2 mice than in WT mice ( Fig. 2b and Extended Data Fig. 3d ). PMT of WT Lys-M GFP knock-in mouse 25 BMDMs into Csf2rb 2/2 mice followed by Ki67 immunostaining revealed that PMT-derived cells replicated in vivo (Extended Data Fig. 3e -g). The percentage of Ki67 1 PMT-derived alveolar macrophages was 32.2 6 6.05% 1 month after PMT and declined to 11.29 6 2.2% by 1 year (Fig. 2c ) similar to baseline Ki67 1 immunostaining of alveolar macrophages in age-matched, normal WT mice (Extended Data Fig. 3f ). To define this survival advantage further, we evaluated the engraftment kinetics after one PMT of WT BMDMs in Csf2rb 2/2 mice. CD131 1 cells increased steadily from zero to 69.0 6 2.5% of BAL cells ( Fig. 2d ) synchronous with a smooth decline in pulmonary GM-CSF to 
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near normal ( Fig. 2e ). Similarly, BAL turbidity declined with the increase in CD131 1 alveolar macrophages ( Fig. 2f) . One year after PMT, CD131 1 cells were present ( Fig. 1b ), CD131 protein (encoded by Csf2rb) was detectable in alveolar macrophages (Extended Data Fig. 3a ), and Csf2rb mRNA in BAL cells from PMT-treated Csf2rb 2/2 mice was only slightly less than in WT and undetectable in untreated Csf2rb 2/2 BAL cells ( Fig. 2g ). Importantly, numbers of CD131 1 alveolar macrophages in PMT-treated Csf2rb 2/2 and untreated WT mice were similar 1 year after PMT (Fig. 2h ). These results demonstrate that WT macrophages had a selective survival advantage over Csf2rb 2/2 macrophages and that after PMT into Csf2rb 2/2 mice, they proliferated in vivo at a rate that slowed over time synchronous with reduction in pulmonary GM-CSF, replaced dysfunctional Csf2rb 2/2 alveolar macrophages, and resulted in numbers of CD131 1 , GM-CSF-responsive alveolar macrophages similar to WT mice.
Macrophage characterization after PMT
The fate of macrophages after PMT was evaluated to determine their spatial distribution, phenotype and gene expression profile. Intra-pulmonary localization was evaluated 1 year after PMT of WT Lys-M GFP BMDMs by fluorescence microscopy to identify CD68 1 GFP 1 (that is, PMT-derived) macrophages, which revealed that 88.9 6 0.87% were intra-alveolar and 11.1 6 0.87% were interstitial (Extended Data Fig. 3h ). GFP immunohistochemical staining was done to eliminate potential interference from autofluorescence and confirmed these results; 90.5 6 1.1% PMT-derived macrophages were intra-alveolar and 9.4 6 1.1% were interstitial ( Fig. 3a, b and Extended Data Fig. 3i ). Localization was done in similarly treated mice by flow cytometry to detect GFP 1 cells 2 months (not shown) or 1 year after PMT (Fig 3c and Extended Data Fig. 4a , b) and by PCR amplification of Lys-M GFP transgene-specific DNA (Extended Data Fig. 4c ), all of which showed that PMT-derived cells were present in the lungs but not detected in blood, bone marrow, or spleen. One year after PMT of CD45.1 1 WT BMDMs into CD45.2 1 Csf2rb 2/2 mice, flow cytometric detection of CD45.1 1 cells confirmed these findings (Extended Data Fig. 4e -g). Results show that the transplanted macrophages remained in the lungs, primarily within the intra-alveolar space. The effects of the lung environment on the phenotype of transplanted macrophages were evaluated by measuring cell-surface markers. One year after PMT of WT Lys-M GFP BMDMs into Csf2rb 2/2 mice, PMTderived alveolar macrophages comprised 68.7 6 6.5% of BAL cells and had converted from CD11b Hi SiglecF Low to CD11b Low SiglecF Hi , similar to the phenotype of WT alveolar macrophages and different from Csf2rb 2/2 mice at the point of PMT (CD11b Hi SiglecF Low ) ( Fig. 3c, d) . Similarly, one year after PMT of WT CD45.1 1 BMDMs into CD45.2 1 Csf2rb 2/2 mice, CD45.1 1 alveolar macrophages comprised 63.6 6 12.1% of BAL cells and had undergone the same phenotypic conversion (Extended Data Fig. 4h ).
To determine the effects on gene expression, we performed genomewide expression profiling on alveolar macrophages from Csf2rb 2/2 mice 1 year after PMT of WT BMDMs and compared to results for untreated, age-matched WT or Csf2rb 2/2 mice. Unsupervised analysis indicated marked co-clustering between PMT-treated Csf2rb 2/2 and WT mice while Csf2rb 2/2 mice clustered separately ( Fig. 4 ). Expression of genes regulated by GM-CSF was reduced in Csf2rb 2/2 mice and restored by PMT ( Fig. 4 and Extended Data Fig. 5a ). Of 776 genes for which expression was disrupted in Csf2rb 2/2 mice, PMT normalized expression of 600 including 80% of genes upregulated and 76% of genes downregulated in Csf2rb 2/2 compared to WT mice (Extended Data Fig. 5b ). Supervised Gene Ontology (GO) and detailed KEGG pathway analysis revealed that genes in multiple pathways involved in lipid metabolism, cellular proliferation, apoptosis and host defence were coordinately downregulated in Csf2rb 2/2 mice, and normalized by PMT (Extended Data Fig. 5c, d) . Results for multiple genes important in lipid metabolism (Abcg1, Nr1h3, Olr1, Lepr, Fabp1, Lipf, Abca1, Apoe, Apoc2, Pla2g7) were validated using separate samples (Extended Data Fig. 5e ).
Efficacy of gene therapy by PMT
Since PMT in humans would probably employ autologous, gene-corrected HSPC-derived macrophages, we evaluated PMT of Csf2rb 2/2 macrophages derived from LSK cells after lentiviral vector (LV)-mediated Csf2rb cDNA expression ( Fig. 5a ). Csf2rb gene-corrected (GM-R-LV-transduced) or sham-treated (GFP-LV-transduced) Csf2rb 2/2 and non-transduced WT LSK-derived cells all had macrophage morphology, expressed CD68 (Extended Data Fig. 6a ) and were F4/80 1 CD11b Hi CD11c 1 (not shown). In contrast, only WT and GM-R-LV-transduced Csf2rb 2/2 cells were CD131 1 and only lentiviral-vector-transduced cells were GFP 1 (Extended Data Fig. 6a ). GM-R-LV restored GM-CSF signalling in Csf2rb 2/2 macrophages ( Fig. 5b and Extended Data Fig. 6b ). Two months after PMT into Csf2rb 2/2 mice, GM-CSF receptor-b was detected on alveolar macrophages only from mice receiving gene-corrected Csf2rb 2/2 or WT macrophages (Extended Data Fig. 6c ). The efficacy using gene-corrected Csf2rb 2/2 or WT cells was equivalent as demonstrated by a similar degree of improvement in BAL appearance (Extended Data Fig. 6d ), BAL turbidity, SP-D and biomarkers of hPAP ( Fig. 5c, d ). Furthermore, gene-corrected BMDMs localized to the lung (Extended Data Fig. 4d and Fig. 6e ) and underwent phenotypic conversion to CD11b Low (Extended Data Fig. 6f ). The long-term efficacy of gene-corrected macrophages 1 year after PMT was demonstrated by marked reduction in BAL turbidity, SP-D and BAL fluid biomarkers of hPAP ( Fig. 5c, d ). These results demonstrate that PMT of gene-corrected macrophages had a therapeutic effect on hPAP in Csf2rb 2/2 mice equivalent to that of WT macrophages and was durable, lasting at least 1 year.
Safety of PMT therapy in Csf2rb 2/2 mice PMT was well tolerated and without adverse effects. One year after PMT, there were no haematological abnormalities (Extended Data Table 4 ), cellular inflammation or pulmonary fibrosis in mice receiving PMT of WT (Fig. 1d ) or gene-corrected macrophages (not shown). Unsupervised hierarchical clustering dendrogram and heat map of selected GM-CSF-regulated genes in PMT-treated Csf2rb 2/2 mice or untreated, age-matched WT or Csf2rb 2/2 mice (3 per group). Pearson correlation coefficient (PCC).
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mice had trivial elevations of IL-6 and TNF-a in BAL that were reduced by PMT of WT macrophages (Extended Data Table 4 ). These data identify no safety concerns for PMT therapy of hPAP in Csf2rb 2/2 mice.
Discussion
Multiple lines of evidence indicate that the high efficacy of PMT therapy of hPAP in Csf2rb 2/2 mice was attributable to a selective survival advantage conferred by increased pulmonary GM-CSF to alveolar macrophages bearing functional GM-CSF receptors. However, pulmonary surfactant remained slightly increased 1 year after a single PMT. This could be because the treatment time was too short or exceeded the durability of the clinical benefit, or due to the continued presence of Csf2rb 2/2 alveolar macrophages despite engraftment of GM-CSF-responsive macrophages. The latter is likely due to ongoing Csf2rb 2/2 myelopoiesis, pulmonary recruitment of monocytes and local proliferation, and GM-CSF-independent survival as occurs in untreated Csf2rb 2/2 mice. Csf2rb 2/2 macrophages may provide a 'protected intracellular niche' for surfactant accumulation since without GM-CSF, alveolar macrophages internalize but cannot clear surfactant 26 . Another factor may be reduction of the survival advantage over time, that is, reduced pulmonary GM-CSF (driving WT cell proliferation) and reduced surfactant burden (driving surfactant-engorgement-related Csf2rb 2/2 cell death). Notwithstanding these points, a single PMT of GM-CSF responsive cells cleared ,90% of the abnormal surfactant accumulation for at least one year.
The feasibility of translating PMT therapy to humans with hPAP is supported by the safety and efficacy of PMT in Csf2rb 2/2 mice and the striking similarity of hPAP in mice and humans. Macrophages could be delivered by bronchoscopic instillation without endotracheal intubation, general anaesthesia, or mechanical ventilation, which are required for whole lung lavage and increase risk. Preparative myeloablation would be unnecessary and use of autologous, gene-corrected cells would eliminate the need for immunosuppression, which are required for BMT. PMT may also be possible with gene-corrected, inducible pluripotentcell-derived macrophages recently prepared from children with hPAP 23, 27 . However, formal preclinical toxicology studies related to PMT and to gene transfer will be needed before this approach can be tested in humans. Since pulmonary GM-CSF is critical to lung host defence and clearance of a broad range of microorganisms 28 , PMT may also be useful in treating serious lung infections. Indeed, pulmonary administration of macrophages constitutively expressing IFN-c improved host defence in SCID mice 29 . In such applications, inhaled GM-CSF could be used to promote survival of transplanted macrophages 30 .
Identification of a homeostatic mechanism by which pulmonary GM-CSF regulates alveolar macrophage population size (Fig. 6) was an unexpected but important finding. Its existence is supported by recent fate-mapping studies indicating that tissue-resident alveolar macrophages derive before birth and self-maintain by local replication independent of circulating monocytes at steady state [30] [31] [32] [33] .
The concept of alveolar macrophages (and other tissue-resident macrophages) as short-lived, terminally differentiated, non-dividing representatives of a unified mononuclear phagocyte system replenished via monocyte intermediates has evolved considerably since its inception 34 . Alveolar macrophage half-life was initially estimated at 2 weeks based on studies of repopulation after lethal irradiation and allogeneic BMT 35 . Improved detection methods using GFP 1 cells increased the estimate to 30 days 36 . Shielding the thorax during irradiation increased it further to 8 months 37 . Our data, obtained without irradiation or myeloablation, show that macrophages transplanted directly into the respiratory tract persisted for one-and-a-half years. A caveat of such estimates is their inability to discern if persistence is due to prolonged survival or replication.
Normally, alveolar macrophages are phenotypically CD11b Low SiglecF Hi while other macrophage populations are CD11b Hi SiglecF Low . Surprisingly, WT BMDMs cultured in GM-CSF and M-CSF were CD11b Hi SiglecF Low in vitro but converted to CD11b Low SiglecF Hi after PMT. In contrast, BMDMs instilled in the peritoneum adopt the CD11b Hi phenotype of peritoneal macrophages 38 . These changes agree with geneexpression profiling studies 39 and indicate that local microenvironments provide critical 'phenotypically instructive' cues that direct development of tissue-resident macrophage populations. Our results show for alveolar macrophages that GM-CSF provides one such phenotypic cue while the lung environment provides another critical, albeit unidentified, cue.
The limitations of our study include the fact that it did not establish a minimum effective dose, a maximum tolerated dose, or a significant dose-response relationship. BMDMs were capable of clearing surfactant before transplantation but results did not determine whether 'lungconditioning' further increased their clearance capacity. While the macrophages used for PMT contained very few progenitors, it is theoretically possible that clonal expansion of a progenitor subpopulation may have contributed to therapeutic efficacy and, if so, potential clonal shrinkage may have contributed to loss of benefit at later times. Thus, additional studies are needed to further confirm the identity of effector cells and precise pharmacokinetics and durability of the therapeutic benefit.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. 
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METHODS
Mice. All mice were bred, housed and studied in the Cincinnati Children's Research Foundation Vivarium using protocols approved by the Institutional Animal Care and Use Committee. Csf2rb gene-targeted (Csf2rb 2/2 ) mice 13 , and mice expressing EGFP knocked into the lysozyme M gene (Lys-M GFP mice) 25 , were all generated previously and backcrossed onto the C57BL/6 background. C57BL/6 mice (referred to as wild type or WT mice) were purchased from Charles River. B6.SJL-Ptprc a Pepc b /BoyJ (CD45.1 1 ) mice were from Jackson Laboratory. Lung histology and immunohistochemistry. Animals were killed by intraperitoneal pentobarbital administration and exsanguination by aortic transection. The trachea was exposed by a vertical midline skin incision, cannulated through a small transverse incision in its ventral surface away from the thoracic inlet, inflated with fixative (PBS, pH 7.4, containing 4% paraformaldehyde) under a hydrostatic head of 25 cm and ligated with suture while retracting the cannula to seal the lung under pressure. The sternum and diaphragm were transected sagittally, retracted laterally, and the lungs and heart separated from the chest wall by blunt dissection to avoid puncturing the mediastinal pleura and removed from the chest. The intact tissue block containing the heart, lungs and ligated trachea was submerged in fixative and kept at 4 uC for 24 h. After fixation, the lung lobes were divided, removed from the tissue block, cut into ,2-mm-thick slices along the long axis, washed in cold PBS, dehydrated, embedded in paraffin, and 5-mm-thick sections were cut and stained with haematoxylin and eosin (H&E), periodic acid-Schiff reagent (PAS), or Masson's trichrome as previously described 40 . Immunostaining for surfactant protein B (SP-B) was done by incubating slides with rabbit anti-SP-B polyclonal antibody (diluted 1:500, Seven Hills Bioreagents, Cincinnati, OH) and Vectastain ABC anti-rabbit immunohistochemical horseradish peroxidase kit (Vector Labs, Inc., Burlingame, CA) and counterstaining with haematoxylin as described 41 . To prepare frozen lung sections, the lungs were inflation fixed in situ as described above and then the heart and lungs were removed en bloc and cryoprotected by sequential immersion in PBS containing increasing sucrose concentrations (10%, 15% and 20%; 8-12 h, 4 uC, at each concentration). The lungs were then embedded in Tissue-Tek OCT compound (Sakura Finetek, Torrance, CA), frozen and stored at 280 uC until use. Serial 6 mm sections were prepared for immunostaining or evaluation of GFP 1 cells. Lung sections and sedimented lung cells were examined by light microscopy using a Zeiss Axioplan 2 microscope (Zeiss) equipped with AxioVision software (Zeiss). Collection, handling and evaluation of bronchoalveolar lavage fluid and cells. Epithelial lining fluid and non-adherent cells were collected from lung surface of mice by bronchoalveolar lavage (BAL) as described 42 and processed immediately. Briefly, five 1-ml aliquots were instilled and immediately recovered per mouse and combined resulting in a BAL recovery of 93.9 6 1.2% per mouse (BAL recovery data for 10 mice evaluated randomly). The photographs of fresh BAL specimens and the specimen after allowing sediment to be formed by overnight incubation at 4 uC were taken. The turbidity of BAL was determined as described 41 . Briefly, after gently mixing to ensure a homogeneous suspension of BAL, a 250 ml aliquot was diluted into 750 ml PBS and the optical density was measured at a wavelength of 600 nm and multiplying the result by the dilution factor. The total number of BAL cells recovered from each mouse was determined by counting cells in an aliquot of known volume using a haemocytometer and multiplying the result by the total volume of BAL and dividing by the volume of the aliquot used for counting. BAL cytology was evaluated in aliquots (,50,000 cells) after sedimentation (Cytospin, Shandon, Inc.; 500 r.p.m., 7 min, room temperature) onto glass slides and staining with DiffQuick, PAS, or oil red O (all from Fisher Scientific) as described 41 . The cell differential was determined by microscopic examination of DiffQuick stained cells and the total number of alveolar macrophages per mouse was determined by multiplying the percentage of alveolar macrophages in BAL cells by the total number of BAL cells recovered 43 . BAL fluid and cells were separated by low-speed centrifugation (285g, 10 min, room temperature) and stored at 280 uC until use (BAL fluid) or immediately evaluated (referred to as BAL cells) or used to isolate alveolar macrophages (see below). Primary alveolar macrophages were purified by brief adherence of BAL cells to plastic as described 18 . Viability was evaluated by Trypan blue exclusion and was $95%. ELISA. The concentration of surfactant protein D (SP-D) in BAL fluid was measured by enzyme-linked immunosorbent assay (ELISA) as we described 41 . The concentration of several cytokines (GM-CSF, M-CSF, MCP-1, IL-1b, IL-6, TNF-a) in BAL fluid and erythropoietin in serum was measured by ELISA (Mouse Quantikine Kits, R&D Systems) as described 1 . Quantitative RT-PCR. Total RNA was isolated from alveolar macrophages using TRIzol Reagent (Life Technologies, Carlsbad, CA) and then used to purify mRNA using RNeasy (Qiagen, Valencia, CA), both as directed by the manufacturers. Purified mRNA was used to synthesize cDNA using the Invitrogen SuperScript III First-Strand Synthesis System (Life Technologies). Standard quantitative RT-PCR (qRT-PCR) was performed as previously described 1 on an Applied Biosystems 7300 Real-Time PCR System (Life Technologies) to measure transcript abundance using TaqMan oligonucleotide primer sets (all from Life Technologies) (Extended Data Table 1 ). Expression of target genes was normalized to the expression of 18s RNA. Data for each gene were shown as the fold change of the mean of results for wildtype mice. Bone-marrow-derived macrophages (BMDMs). Bone marrow cells were obtained from 6-8-week-old WT, Csf2rb 2/2 , or Lys-M GFP mice by isolating and flushing tibias and femurs with DMEM (Life Technologies) containing 10% heat-inactivated FBS, 50 U ml 21 penicillin, and 50 mg ml 21 streptomycin. After red blood cells were removed with BD Pharm Lyse (BD Biosciences), mononuclear cells were isolated by centrifugation on Ficoll-Paque (GE Healthcare) at room temperature for 30 min, washed, re-suspended in DMEM containing 10% heat-inactivated FBS, 50 U ml 21 penicillin, 50 mg ml 21 streptomycin, 10 ng ml 21 GM-CSF and 5 ng ml 21 M-CSF (both from R&D Systems), seeded into plastic dishes (Falcon) at a density of ,27 3 10 6 cells per 10 cm dish (1 per mouse) and cultured overnight at 37 uC in a humidified environment containing 5% CO 2 . The next day, non-or weakly-adherent cells were recovered, transferred to a new dish and cultured under the conditions just described to permit differentiation and expansion of macrophages; firmly adherent cells were discarded. After 2 days the culture medium was changed and after 5 days from seeding, adherent bone-marrow-derived macrophages were gently washed with PBS, harvested by brief exposure to trypsin-EDTA (Life Technologies), washed, and used for experiments. The cell purity was high as indicated by the percentage of CD68 1 and F4/80 1 cells (96.6 6 0.3%, 95.4 6 1.3%, respectively, not shown).
Some experiments used lineage-negative (Lin 2 ) c-Kit 1 Sca-1 1 (LSK) cells which were obtained from mouse bone marrow as described 44 . Briefly, bone marrow from 6-8-week-old WT or Csf2rb 2/2 mice was collected as above and lineage depleted with biotinylated lineage antibodies CD5 (53-7.3), CD8a (53-6.7), CD45R/B220 (RA3-6B2), CD11b (M1/70), Gr-1 (RB6-8C5), and TER-119 (TER-119) (BD Bioscience), and magnetic beads (Dynabeads sheep anti-rat IgG) (Life-Technologies). After removing lineage-positive cells, the remaining cells were stained with 7-ADD, FITC-Streptavidin (BD Biosciences) and antibodies to Sca-1 (D7) and c-Kit (2B8) (BD Biosciences). Then, Lin 2 c-Kit 1 Sca-1 1 7-ADD 2 cells were isolated by cell sorting on a FACSAria (BD Biosciences) and used immediately in experiments. Cell morphology was confirmed by DiffQuick Staining of sedimented cells (Cytospin, Shandon) and viability was measured by Trypan blue exclusion as described 18 and found to be $95%. In some experiments, cells were immunostained for CD68 (FA-11) (AbD Serotec), counterstained with DAPI as described 41 , and examined by light microscopy using a Zeiss Axioplan 2 microscope (Zeiss) equipped with AxioVision software (Zeiss). Colony forming cell (CFC) assay. BMDMs or Linbone marrow cells were evaluated for the presence of haematopoietic progenitors capable of forming colonies in semisolid medium in response to cytokine stimulation as previously described 45 . Briefly, fresh Lin 2 bone marrow cells or BMDMs after induced differentiation into macrophages for 5 days were seeded into standard mouse methylcellulose media supplemented with insulin, transferrin, SCF, IL-3, IL-6 and erythropoietin (HSC007, R&D Systems, Minneapolis, MN). After 7 days in culture, colonies of $50 cells were visible and were examined morphologically using whole-plate stack images acquired using an AXIO-Z1 microscope and AXIO-vision software (Zeiss, Jena, Germany) to identify and enumerate burst-forming erythroid progenitors (BFU-E), colonyforming myeloid progenitors (CFU-GM) and the multi-potential progenitors (CFU-GEMM). Surfactant clearance assay. BMDMs were evaluated functionally to demonstrate their ability to clear human surfactant as we previously reported 41 . Briefly, BMDMs from either WT or Csf2rb 2/2 mice were seeded into 12-well plates (4 3 10 5 cells per well) in DMEM, 10% FBS, 10 ng ml 21 GM-CSF, 5 ng ml 21 M-CSF. Human surfactant recovered by lavage of a patient with PAP was added to the media and cells were incubated for 24 h to permit surfactant uptake into cells and then washed to remove extracellular surfactant. Cells were incubated for 24 h to permit macrophages to clear internalized surfactant. Cells collected before, immediately after surfactant exposure or 24 h after the completion of surfactant exposure were sedimented onto slides by cytocentrifugation (Shandon), stained with oil red O, and counterstained with haematoxylin. Oil red O staining was evaluated in $10 random 203 microscopic fields for each sample as described 41 . Pulmonary macrophage transplantation (PMT). BMDMs or LSK cell-derived macrophages were administered directly into the lungs of 8-week-old mice using a relatively non-invasive endotracheal instillation method described previously 46 . Briefly, mice received light anaesthesia by isoflurane inhalation and were suspended on a flat board by a rubber band across the upper incisors and placed in a semirecumbent (45u) position with the ventral surface and rostrum facing upwards. Using a curved blade Kelly forceps, the tongue was gently and partially retracted rostrally, and 50 ml of PBS containing the macrophages to be administered was placed in the back of the oral cavity using a micropipette. The PBS and cells were inhaled into the lungs by subsequent respiratory efforts under direct visualization. Mice were then observed while recovering from anaesthesia to ensure continued ARTICLE RESEARCH time of 3 days; and (4) macrophage differentiation: GM-CSF 10 ng ml 21 and M-CSF 5 ng ml 21 , culture time of 4 days. StemSpan (STEMCELL Technologies) containing 2% FBS, 1% penicillin/streptomycin, 10 mM dNTP, and low-density lipoprotein was used as the culture medium for the LSK transduction and DMEM with 10% FBS, 50 U ml 21 penicillin and 50 mg ml 21 streptomycin was used for all other stages. Phenotype markers (F4/80, CD11b, CD11c) were analysed by flow cytometry at each stage to monitor macrophage differentiation. Only adherent macrophages at the end of this procedure were used for PMT. Localization of PMT-derived cells after transplantation. Several approaches were used to identify and localize PMT-derived cells within the lung parenchyma and in different organs. Intra-pulmonary localization of PMT-derived cells. CD131 immunostaining and fluorescence microscopy or flow cytometry was used to detect and quantify transplantation-derived donor macrophages among BAL cells from the lungs of Csf2rb 2/2 mice that previously received PMT of WT (C57BL/6) BMDMs, Lys-M GFP BMDMs, CD45.1 1 WT BMDMs, or GM-R-GFP-LV Csf2rb gene-corrected Csf2rb 2/2 LSK-derived macrophages.
To localize PMT-derived macrophages to intra-alveolar space or interstitium of the lung, frozen lung sections from mice that received PMT of Lys-M GFP BMDMs 1 month or 1 year earlier were immunostained with CD68, counterstained with DAPI (Vector Labs) and evaluated by fluorescence microscopy to identify macrophages, PMT-derived cells, and nucleated cells, respectively. PMT-derived macrophages (that is, GFP 1 CD68 1 cells) located within the intra-alveolar space or the interstitium were then enumerated. To eliminate the possibility of any interference from non-specific auto-fluorescence of alveolar macrophages, paraffin-embedded lung sections from these mice were immunostained with anti-GFP antibody (Life Technologies) and examined by light microscopy to enumerate immunohistochemically marked macrophages located within the intra-alveolar space or interstitium. Organ-specific localization of PMT-derived cells. In one approach, Csf2rb 2/2 mice received PMT of Lys-M GFP BMDMs and 1 year later, cells isolated from the BAL, blood, bone marrow, and spleen were evaluated by flow cytometry to detect GFP 1 cells as a marker for PMT-derived cells.
In a second approach, CD45.2 1 Csf2rb 2/2 mice received PMT of CD45.1 1 BMDMs and 1 year later, cells isolated from the BAL, blood, bone marrow and spleen were evaluated by flow cytometry to detect CD45.1 1 cells as a marker for PMTderived cells.
In a third approach, Csf2rb 2/2 mice received PMT of Lys-M GFP BMDMs and 1 year later, DNA was extracted from the BAL cells (lung), blood leukocytes, bone marrow cells, and spleen using a DNeasy Blood & Tissue Kit (Qiagen). Organspecific DNA was subjected to PCR amplification using oligonucleotide primers (Extended Data Table 1 ) specific for the Lys-M GFP knock-in transgene or the unmodified Lysozyme M gene to detect PMT-derived and endogenous cells, respectively, as previously reported 25 .
A fourth approach was conducted using a specific operating procedure (TSL 6-13) and Good Laboratory Practice (GLP) conditions within the CCHMC Translational Core Laboratory. Here, DNA was extracted from the BAL cells (lung), blood leukocytes, bone marrow cells, and spleen of Csf2rb 2/2 mice that had received PMT of GM-R-GFP-LV Csf2rb gene-corrected, Csf2rb 2/2 LSK-derived macrophages 1 year earlier and subjected to quantitative PCR amplification with oligonucleotide primers specific for the R-U5 of GM-R-GFP-LV using Applied Biosystems ABI7900HT Fast Real-Time PCR System (Life Technologies). The number of GM-R-GFP-LV vector copies per microgram of organ-specific DNA was quantified and normalized to the level of mouse apolipoprotein B gene as described previously 54 .
Statistical analysis. Numeric data were evaluated for normality and variance using the Shapiro-Wilk and Levene median tests, respectively, and presented as mean 6 s.e.m. (parametric data) or median and interquartile range (nonparametric data). Statistical comparisons were made with Student's t-test, one-way analysis of variance, or Kruskal-Wallis rank-sum test as appropriate; post-hoc pairwise multiple comparison procedures were done using the Student-Newman-Keuls or Dunn's method as appropriate. P values of #0.05 were considered to indicate statistical significance. Based on the use of BAL turbidity (the primary outcome variable for efficacy) measured 2 months after PMT of WT BMDMs into Csf2rb 2/2 mice and compared to age-matched, untreated Csf2rb 2/2 mice, 6 mice per group had a power 0.8 to detect a difference of 1.4 OD 600 nm using a two-tailed Student's t-test and a P value of 0.05. All studies used male and female mice by randomly assigning mice housed in the same cage to separate experimental groups but without formal randomization or blinding. Results from all mice were included in the final analysis without exclusion. Analyses, including Kaplan-Meyer survival analysis, were performed with SigmaPlot, Version 12.5 (Systat Software, San Jose, CA). All experiments were repeated at least twice, with similar results.
